Is self-sufficiency in haemotherapies a practical or necessary goal?

Blood Transfusion

Volumn 11, Issue 2, 2013, Pages 183-192

  Farrugia, Albert ^a,b   Cassar, Josephine ^c  

^a The Australian National University   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Access; Evidence; Haemotherapies; Medicines

Indexed keywords

IMMUNOGLOBULIN;

APHERESIS; AWARENESS; BLOOD BANK; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAFETY; BLOOD SAMPLING; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; CLINICAL PRACTICE; CONTROL SYSTEM; DEMOGRAPHY; ERYTHROCYTE; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; MEDICAL ETHICS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VASCULARIZATION;

BLOOD BANKS; BLOOD DONORS; BLOOD SAFETY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; ORGANIZATIONAL POLICY;

EID: 84876918543     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0148-12     Document Type: Review

References (62)

1. WHO Expert Group. Expert Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary non-remunerated blood donation (VNRBD). Vox Sang 2012;103:337-42.
2. Royal Commission of Inquiry on the Blood System in Canada. Final Report Vol. 1. 1996. p. 63-4. Available at: http://epe. lac-bac.gc.ca/100/200/301/hcan- scan/commission-blood-final-rep-e/vol1-e.pdf. Accessed on 02/07/2012.
3. Royal Commission of Inquiry on the Blood System in Canada. Final Report Vol. 3;1996. p. 1048. Available at: http://epe. lac-bac.gc.ca/100/200/301/hcan- scan/commission-blood-final-rep-e/vol3-e.pdf. Accessed on 02/07/2012.
4. Rickard KA, Batey RG, Dority P, et al. Hepatitis and haemophilia therapy in Australia. Lancet 1982;2:146-8. (Pubitemid 12075587)
5. de Montalembert M, Costagliola DG, Lefrère JJ, et al. Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. The French Study Group On Thalassaemia. Transfusion 1992;32:509-12.
6. Farrugia A. Globalisation and blood safety. Blood Rev 2009;23:123-8.
7. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005. (Pubitemid 36569988)
8. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010;38:20-30.
9. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
10. Farrugia A, Penrod J, Bult J. Payment, compensation and replacement - The ethics and motivation of blood and plasma donation. Vox Sang 2010;99:202-11.
11. Rinaldi G. Italy: national policy. Pharmaceuticals Policy and Law 7 (2005, 2006) 243-53.
12. Commission of the European Communities. Report on the promotion by Member States of voluntary unpaid blood donations. Available at http://ec.europa.eu/ health/ph-threats/human-substance/documents/blood-com-0217-en.pdf. Accessed on 06/07/2012.
13. Sanchez AM, Ameti DI, Schreiber GB, et al. The potential impact of incentives on future blood donation behaviour. Transfusion 2001;41:172-8. (Pubitemid 32220505)
14. Beck S. Blood centers and plasma centers - mutual benefit. Available at: http://www.pptaglobal.org/UserFiles/file/TheSource/2011/summer/ 201106-12-BLOOD-CENTERS-AND-PLASMA-CENTERS-MUTUAL-BENEFIT.pdf. Accessed on 02/07/2012.
15. Farrugia A. More blood, more life? Reflections on World Blood Donor Day - 2011. Indian J Med Res 2011;133:573-6.
16. World Medical Association. Lisbon Declaration of the Rights of the patient 1981. Available at: http://www.wma.net/en/30publications/10policies/l4/ index.html.pdf?print-mediatype&footer-right=[page]/[toPage] Accessed on 02/07/2012.
17. Bruce D. Erie blood bank battles economy, competition. Available at: http://www.goerie.com/apps/pbcs.dll/article?AID=/20100722/NEWS02/307229932. Accessed on 06/09/2012.
18. Beauchamp K. Red alert! Is regulation working for imported and CSL blood products? Australian Institute of Criminology 1995. Available at: http://www.criminologyresearchcouncil. gov. au/reports/37-91-a.pdf. Accessed on 07/12/2012.
19. Royal Commission of Inquiry on the Blood System in Canada. The Bureau of Biologics and the Regulation of Blood and Blood Products. Report of the Royal Commission of Inquiry on the Blood System in Canada 1997; vol 1:111-147. Available at: http://publications.gc.ca/collections/Collection/CP32-62-3-1997- 1E.pdf. Accessed on 06/09/2012.
20. Steffen M. The nation's blood: medicine, justice, and the state in France. In Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster. Feldman E, Bayer R (ed) Oxford University Press 1999, p. 95-126.
21. Saberton PJ, Paez A, Newbold KB, Heddle NM. Geographical variations in the correlates of blood donor turnout rates: an investigation of Canadian metropolitan areas. Int J Health Geogr 2009;8:56.
22. Serious Hazards of Transfusion. Annual Report 2008. Available at: http://www.shotuk.org/wp-content/uploads/2010/03/SHOT-Report-2008.pdf. Accessed on 02/07/2012.
23. World Health Organization. Global Data Base for Blood Safety - Summary Report 2011. Available at: http://www.who.int/bloodsafety/global-database/GDBS- Summary-Report-2011.pdf. Accessed on 06/09/2012.
24. Council of Europe. The Collection, Testing and Use of Blood and Blood Components in Europe 2008. Available at: http://www.edqm.eu/medias/fichiers/The- Collection-Testing-and-Use-of-Blood-and-Blood-3.pdf. Accessed on 06/09/2012.
25. World Health Organization. Status of blood safety in the WHO African Region - Report of the 2006 Survey, page X. Available at: http://www.afro.who. int/index.php?option=com-docman&task=doc-download&gid=3835. Accessed on 06/09/2012.
26. Organisation for Economic Co-operation and Development. Key indicators of Health Data 2012. Available at: http://www.oecd.org/els/healthpoliciesanddata/ OECDHealthData2012Fre quentlyRequestedData-Updated.xls. Accessed on 06/09/2012.
27. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of red blood cells. Blood Transfus 2009;7:49-64.
28. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;157:49-58.
29. Stonebraker JS, Amand RE, Bauman MV, et al. Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia 2004;10:18-26. (Pubitemid 38202136)
30. Strategic Blood Management. Case studies. Available at: http://www.bloodmanagement.com/case-studies/case-studies. Accessed on 06/09/2012.
31. Farrugia A. Iron and blood donation - an under-recognised safety issue. Dev Biol (Basel). 2007;127:137-46.
32. World Health Organization. Global blood safety and availability. Facts and figures from the 2007 Blood Safety Survey, 2009. Available at: http://www.who.int/mediacentre/factsheets/fs279/en/print.html. Accessed on 02/07/2012.
33. Rogo KO, Oucho J, Mwalali P. Maternal Mortality. In: Jamison DT, Feachem RG, Makgoba MW, et al., editors. Disease and Mortality in Sub-Saharan Africa. 2nd edition. Washington (DC): World Bank; 2006. p. 223-36.
34. Allain JP. Moving on from voluntary non-remunerated donors: who is the best blood donor? Br J Haematol 2011;154:763-9.
35. Farrugia A, Cassar J. Plasma-derived medicines: access and usage issues. Blood Transfus 2012;10:273-8.
36. Centers for Medicare and Medicaid Services USA. Data extracted for IG use by physicians. Extracted through application in 2010. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/CMS-Information- Technology/AccesstoDataApplication/index.html. Accessed on 07/12/2012.
37. Australian National Blood Authority. Top ten uses for IVIG 2004-11. Available at: http://www.nba.gov. au/publications/1011report/images/content/ figure-3.19.gif. Accessed on 07/09/2012.
38. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(Suppl. 4):S525-53.
39. Australian National Blood Authority. Criteria for the clinical use of intravenous immunoglobulin. 2nd edition 2012. Available at: http://www.nba.gov. au/ivig/pdf/criteria.pdf. Accessed on 06/09/2012.
40. Mark SM. Comparison of intravenous immunoglobulin formulations: product, formulary, and cost considerations. Hosp Pharm 2011;46:668-76.
41. Rossi F, Perry R, de Wit J, et al. How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems? Vox Sang 2011;101:176-7.
42. Stonebraker J, Farrugia A. Using decision analysis to model latent therapeutic demand for immunoglobulin in treating CVID. J Clin Immunol 2012;32:399.
43. National Blood Authority of Australia. Annual Report 2009-10; p. 55. Available at: http://www.nba.gov. au/publications/0910report/prelims/contents. html. Accessed on 07/12/2012.
44. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010;98:12-28.
45. Smit Sibinga C Th, Das PC. Use and abuses of single donor plasma. In: Kollins J, Britten AFH, Silvergleid editors. Plasma Products: Use and Management. American Association of Blood Banks: Arlington VA USA; 1982. p. 23-32.
46. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011;39:386-91.
47. Robert P. Worldwide supply and demand of plasma and plasma-derived medicines. Iran J Blood Cancer 2011, 3:111-20.
48. Laub R, Baurin S, Timmerman D, et al. Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations. Vox Sang 2010;99:220-31.
49. Schulzki T, Seidel K, Storch H, et al; SIPLA study group. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). Vox Sang 2006;91:162-73. (Pubitemid 44126613)
50. Council of Europe. Guide to the preparation, use and quality assurance of blood components. Recommendation No. R (85) 15, Council of Europe Publishing, Strasbourg.
51. Council of Europe. Trends and Observations on the Collection, Testing and Use of Blood and Blood components in Europe 2001-2005. Council of Europe, February 2011.
52. Food and Drug Administration. Code of Federal Regulations - PART 640-Additional Standards for human bloo and blood products. Available at: http://law.justia.com/cfr/title21/21-7.0.1.1.7.html. Accessed on 07/12/2012.
53. Andreasen JJ, Dethlefsen C, Modrau IS, et al. North-West Denmark Transfusion Study Group. Storage time of allogeneic red blood cells is associated with risk of severe postoperative infection after coronary artery bypass grafting. Eur J Cardiothorac Surg 2011;39:329-34.
54. Bowling F, Pennardt A. The use of fresh whole blood transfusions by the SOF medic for hemostatic resuscitation in the austere environment. J Spec Oper Med 2010;210:25-35.
55. European Commission. Council Directive 89/381/EEC of 14 June 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products and laying down special provisions for medicinal products derived from human blood or human plasma. Available at: http://www.ikev.org/docs/eu/389L0381.htm. Accessed on 07/12/2012.
56. Robertson J. Hemato-nationalism: the past, present, and future of "Japanese blood". Med Anthropol 2012;31:93-112.
57. Bult JM. In my view, continued challenges of doing business in Japan. The Source Spring 2011. Available at: http://www.pptaglobal.org/UserFiles/file/ TheSource/2011/spring/201103-2-IN-MY-VIEW.pdf. Accessed on 07/12/2012.
58. Blood Products Research Organization. Blood Program in Japan 2011. Available at: http://www.bpro.or.jp/english/pdf-annual/BPRP2011.pdf. Accessed on 07/09/2012.
59. O'Mahony B. EU self sufficiency - The patients perspective. Available at: http://www.haemophilia.ie/PDF/BOMahony%20 lecture%204%20IPPC%20Berlin.pdf. Accessed on 07/09/2012.
60. Buciuniene I, Stonienë L, Blazeviciene A, et al. Blood donors' motivation and attitude to non-remunerated blood donation in Lithuania. BMC Public Health 2006;6:166.
61. Kalibatas V. Payment for whole blood donations in Lithuania: the risk for infectious disease markers. Vox Sang 2008;94:209-15. (Pubitemid 351379654)
62. Greinacher A, Fendrich K, Brzenska R, et al. Implications of demographics on future blood supply: a population-based cross-sectional study. Transfusion 2011;51:702-9.